[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR880011088A - 페닐 카르바메이트 - Google Patents

페닐 카르바메이트 Download PDF

Info

Publication number
KR880011088A
KR880011088A KR1019880002187A KR880002187A KR880011088A KR 880011088 A KR880011088 A KR 880011088A KR 1019880002187 A KR1019880002187 A KR 1019880002187A KR 880002187 A KR880002187 A KR 880002187A KR 880011088 A KR880011088 A KR 880011088A
Authority
KR
South Korea
Prior art keywords
compound
formula
ethyl
pharmaceutically acceptable
acid addition
Prior art date
Application number
KR1019880002187A
Other languages
English (en)
Other versions
KR0133686B1 (ko
Inventor
엔쯔 알버트
Original Assignee
쟌 크라메르
산도즈 리미티드
한스 루돌프 하우스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880011088(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 쟌 크라메르, 산도즈 리미티드, 한스 루돌프 하우스 filed Critical 쟌 크라메르
Publication of KR880011088A publication Critical patent/KR880011088A/ko
Priority to KR96013694A priority Critical patent/KR970005836B1/ko
Application granted granted Critical
Publication of KR0133686B1 publication Critical patent/KR0133686B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

페닐 카르바메이트
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 대응되는 라세메이트로 부터 거울상 이성체를 분리하고 생성된 식 (Ⅰ)의 화합물을 유리염기 또는 산부가염의 형태로 회수하는 것으로 구성된 유리염기 또는 산부가염 형태의 하기식(Ⅰ)의 (S)-N-에틸-3-[(1-디메틸아미노)에틸]-N-페닐-카르바메이트의 제조방법.
  2. 실시예에 서술된 방법과 같은 방법에 의한 유리염기 또는 산부가염형태의 제1항에 따른 식 (Ⅰ) 화합물의 제조방법.
  3. 제1항에서 정의된 유리염기 또는 산부가염형의 식 (Ⅰ)의 화합물.
  4. 제3항에 있어서, (S)-N-에틸-3-[(1-디메틸아미노)에틸]-N-메틸-페닐-카르바메이트의 타르타르산수소인 화합물.
  5. 제3항 또는 제4항에 있어서, 약학적 제제로 사응하기 위한 약학적 허용 가능한 형의 화합물.
  6. 제3항 또는 제4항에 있어서, 노인성 치매의 치료에 사용하기 위한 약학적 허용가능한 형의 화합물.
  7. 제3항 또는 제4항에 있어서, 알쯔하이머 질병의 치료에 사용하기 위한 약학적 허용 가능한 형의 화합물.
  8. 제3항 또는 제4항에 있어서, 헌팅톤 무도병, 만성운동장해, 과운동장해, 조병, 급성착란증, 다운증후군 또는 프리드리히 실조증의 치료에 사용하기 위한 약학적 허용 가능한 형의 화합물.
  9. 약학적 허용 가능한 형의 제3항 또는 제4항의 화합물과 약학적 담체 또는 희식제로 구성된 약학적 조성물.
  10. 유리염기 또는 약학전으로 허용 가능한 산부가염 형태의 하기식(Ⅰ')의 화합물과 계통적 경피투여를 위한 약학적 담체 또는 희석제로 구성된 계통적 경피 투여용 약학적 조성물.
    상기식에서, R1은 수소, 저급알킬, 시클로헥실, 알릴 또는 벤질, R2는 수소, 에틸, 에틸, 또는 프로필, 또는 R1과 R2는 함께 그들이 부착된 질소원자와 더불어 모르폴린 또는 피페리디노라디칼을 형성, R3은 수소 또는 저급알킬, R4와 R5는 같거나 다르며 각각 저급알킬이며 디알킬아미노알킬은 데타, 오르토 또는 파라위치에 있다.
  11. 제10항에 있어서, 식 (Ⅰ')의 화합물이 유리염기 또는 약학적으로 허용 가능한 산부가염형의 (S)-N-에틸-3-1 (1-디메틸아미노)-에틸]-N-메틸-페닐-카르바메이트인 조성물.
  12. 제10항에 있어서, 식 (Ⅰ')의 화합물이 타르타르산 수소형의 (S)-N-에틸-3-[(1-디메틸아미노)-에틸]-N-메틸-페닐-카르바메이트인 조성물.
  13. 제10항에 있어서, 식 (Ⅰ')의 화합물이 유리염기 또는 약학적으로 허용가능한 산부가염형의 N-에틸-3-[(1-디메틸아미노)-에틸]-N-메틸-페닐-카르바메이트인 조성물.
  14. 제10항에서 정의된 유리임기 또는 약학적으로 허용 가능한 산부가염형의 식 (Ⅰ')의 화합물을 계통적 경피 적용을 위한 약학적 조성물의 제조에 사용하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880002187A 1987-03-04 1988-03-03 페닐 카르바메이트 KR0133686B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR96013694A KR970005836B1 (en) 1987-03-04 1996-04-30 Pharmaceutical composition of phenyl carbamate for subcutaneous administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CHP3706914.4 1987-03-04
DE3706914 1987-03-04

Publications (2)

Publication Number Publication Date
KR880011088A true KR880011088A (ko) 1988-10-26
KR0133686B1 KR0133686B1 (ko) 1998-04-21

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880002187A KR0133686B1 (ko) 1987-03-04 1988-03-03 페닐 카르바메이트

Country Status (29)

Country Link
US (1) US5602176A (ko)
JP (3) JP2625478B2 (ko)
KR (1) KR0133686B1 (ko)
AT (1) AT394190B (ko)
AU (1) AU618949B2 (ko)
BE (1) BE1001467A3 (ko)
CA (1) CA1307003C (ko)
CH (1) CH675720A5 (ko)
CS (1) CS411091A3 (ko)
CY (1) CY1735A (ko)
DK (1) DK175762B1 (ko)
ES (1) ES2010527A6 (ko)
FI (1) FI89165C (ko)
FR (1) FR2611707B1 (ko)
GB (1) GB2203040C (ko)
GR (1) GR1000023B (ko)
HK (1) HK110093A (ko)
HU (1) HU201906B (ko)
IE (1) IE61714B1 (ko)
IL (1) IL85609A (ko)
IT (1) IT1219853B (ko)
LU (2) LU87150A1 (ko)
MY (1) MY103225A (ko)
NL (1) NL195004C (ko)
NZ (1) NZ223714A (ko)
PT (1) PT86875B (ko)
SA (1) SA93140384B1 (ko)
SE (1) SE8800731A0 (ko)
ZA (1) ZA881584B (ko)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
EP0755685A4 (en) * 1994-04-15 2000-05-03 Meiji Seika Kaisha PHARMACEUTICAL COMPOSITION FOR TREATING LATE DYSKINESIA
PT951284E (pt) * 1996-12-18 2003-12-31 Yissum Res Dev Co Derivados de feniletilamina
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
WO1998027055A1 (en) 1996-12-18 1998-06-25 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
JP4012689B2 (ja) 1998-10-01 2007-11-21 ノバルティス アクチエンゲゼルシャフト 新規徐放性経口製剤
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
EP1137414B1 (en) * 1998-12-11 2005-10-12 Bonnie M. Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) * 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ20023555A3 (cs) 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
WO2004037234A2 (en) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
EP1689704A2 (en) * 2003-10-21 2006-08-16 CoLucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
KR101168211B1 (ko) * 2004-11-08 2012-07-25 엠큐어 파마슈티컬즈 리미티드 （ｓ）－３－［（１－디메틸아미노）에틸］－페닐－ｎ－에틸－ｎ－메틸－카바메이트의 제조를 위한 효과적인 방법
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
JP2009502807A (ja) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
JP5116679B2 (ja) 2005-09-15 2013-01-09 株式会社ソニー・コンピュータエンタテインメント 強度のコンピュータ画像および音声処理、ならびにコンピュータプログラムとインタフェースするための入力装置
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
BRPI0620659A2 (pt) * 2005-12-09 2017-10-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
CA2661009A1 (en) * 2006-08-17 2008-02-21 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
US20100152108A1 (en) 2006-10-27 2010-06-17 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
WO2008097546A2 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20090048229A1 (en) * 2007-07-18 2009-02-19 Rupniak Nadia M J Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
EP2233465B1 (en) * 2008-01-10 2017-06-28 Shanghai Institute of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
US8420846B2 (en) 2008-08-25 2013-04-16 Jubilant Life Sciences Limited Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) * 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
WO2011076621A2 (de) 2009-12-22 2011-06-30 Acino Ag Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
JP6082250B2 (ja) 2010-02-09 2017-02-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 認知機能を改善するための方法および組成物
SG183806A1 (en) 2010-03-29 2012-10-30 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011159910A2 (en) 2010-06-17 2011-12-22 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
CN103313712B (zh) 2010-11-15 2016-10-26 艾吉因生物股份有限公司 用于治疗认知障碍的哒嗪衍生物、组合物和方法
PL2468274T3 (pl) 2010-12-14 2015-11-30 Luye Pharma Ag Przezskórny układ terapeutyczny do podawania substancji czynnej
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
US9585862B2 (en) 2011-05-20 2017-03-07 Sk Chemicals Co., Ltd. Patch containing rivastigmine
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
US9333182B2 (en) 2011-08-31 2016-05-10 Sekisui Medical Co., Ltd. Adhesive patch
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
WO2015022418A1 (en) 2013-08-16 2015-02-19 Takeda Gmbh Treatment of cognitive impairment with pde4 inhibitor
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
MX2017015752A (es) 2015-06-19 2018-04-13 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2020013927A (es) 2018-06-19 2021-03-02 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
SE8800731L (sv) 1988-09-05
FI880972A0 (fi) 1988-03-02
CY1735A (en) 1994-06-03
FI89165C (fi) 1993-08-25
NL195004B (nl) 2003-07-01
FI880972A (fi) 1988-09-05
GB2203040B (en) 1990-10-24
HK110093A (en) 1993-10-29
JPS63238054A (ja) 1988-10-04
IT8847693A0 (it) 1988-03-04
JP2859225B2 (ja) 1999-02-17
IL85609A0 (en) 1988-08-31
KR0133686B1 (ko) 1998-04-21
AU1255488A (en) 1988-09-08
ATA55188A (de) 1991-08-15
JP2625478B2 (ja) 1997-07-02
NZ223714A (en) 1994-05-26
SA93140384B1 (ar) 2006-04-04
JPH09118617A (ja) 1997-05-06
HUT49325A (en) 1989-09-28
MY103225A (en) 1993-05-29
LU87150A1 (fr) 1988-11-17
SE8800731D0 (sv) 1988-03-02
FR2611707B1 (fr) 1990-04-20
FR2611707A1 (fr) 1988-09-09
IE61714B1 (en) 1994-11-30
AT394190B (de) 1992-02-10
CS411091A3 (en) 1992-12-16
GB8804888D0 (en) 1988-03-30
HU201906B (en) 1991-01-28
NL8800436A (nl) 1988-10-03
DK175762B1 (da) 2005-02-14
BE1001467A3 (fr) 1989-11-07
AU618949B2 (en) 1992-01-16
GR1000023B (el) 1990-01-31
IL85609A (en) 1992-07-15
SE8800731A0 (sv) 1988-09-05
US5602176A (en) 1997-02-11
DK112588D0 (da) 1988-03-02
DK112588A (da) 1988-09-05
PT86875A (pt) 1988-04-01
ES2010527A6 (es) 1989-11-16
CH675720A5 (ko) 1990-10-31
PT86875B (pt) 1992-05-29
IE880583L (en) 1988-09-04
CA1307003C (en) 1992-09-01
LU90297I2 (fr) 1998-12-07
IT1219853B (it) 1990-05-24
JPH09165362A (ja) 1997-06-24
GB2203040A (en) 1988-10-12
FI89165B (fi) 1993-05-14
GR880100125A (en) 1989-01-31
NL195004C (nl) 2003-11-04
GB2203040C (en) 2014-07-30
ZA881584B (en) 1989-11-29

Similar Documents

Publication Publication Date Title
KR880011088A (ko) 페닐 카르바메이트
KR860007207A (ko) 페닐 카르바메이트 및 이것의 염을 제조하는 방법
KR930701402A (ko) N- 하이드로 카르빌 -4- 치환된 피페리딘, 이들의 제조 방법 및 이들의 칼슘 차단제로서의 용도
JP2006501295A5 (ko)
EP1200395A1 (en) Urea derivatives as inhibitors of ccr-3 receptor
JP2003519208A (ja) （ｒｒ，ｓｓ）−３−（２−ジメチルアミノメチル−１−ヒドロキシシクロヘキシル）フェニル２−ヒドロキシベンゾエートから誘導される新規エステル
RU98108553A (ru) Фармацевтические композиции, содержащие производные гидроксимикоевой кислоты
KR920701176A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조 방법 및 그의 치료 용도
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
KR910009707A (ko) 피소스타그민에 관련된 아미노카보닐카바메이트, 이의 제조방법 및 이의 약제로서의 용도
RU2006113550A (ru) Циклогексильные производные, замещенные аминоалкиламидами
EP1069125A3 (en) Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs, a process for their preparation and their use as medicaments
KR910016695A (ko) 4-(아미노메틸) 피페리딘 유도체, 그의 제조방법 및 치료에의 이용
KR870007099A (ko) 아민유도체의 제조방법
KR900011724A (ko) 특정 피롤릴페닐-치환된 하이드록삼산 유도체
KR880001593A (ko) 4-(아로일아미노)피페리딘부탄아미드 유도체
GB1289240A (ko)
KR910016691A (ko) 신규한 치환된-아민 화합물 및 그의 제조방법
CA2180621A1 (fr) Nouveaux derives d'acide aminophenylphosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US2899434A (en) Z-phenylamino-l
DK0556813T3 (da) Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler
EP3107906B1 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
KR880007506A (ko) 카바모일옥시라브단, 중간체 및 그의 제조방법 및 용도
US9090595B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
CA2429267A1 (fr) Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant

Legal Events

Date Code Title Description
AMND Amendment
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

B701 Decision to grant
GRNT Written decision to grant
J204 Request for invalidation trial [patent]
EXPY Expiration of term
J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20121115

Effective date: 20131220

J2X1 Appeal (before the patent court)

Free format text: INVALIDATION

J202 Request for trial for correction [limitation]
J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20140307

Effective date: 20140912

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20140121

Effective date: 20141107

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2017240006804; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20170921

Effective date: 20180907

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2018300011629; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20181010

Effective date: 20190131